Consolidated Financial Results for the 1st Quarter and Full-year Forecasts for Fiscal 2023

from the beginning

Consolidated Financial Results for the 1st Quarter and Full-year Forecasts for Fiscal 2023

@

• Highlights

• 01. Consolidated Financial Results and Business Review for the 1Q of Fiscal 2023 (FY Ending March 31, 2023)

1Q of Fiscal 2023 (1) Consolidated Financial Results

1Q of Fiscal 2023 (2) Endoscopic Solutions Division (ESD)

1Q of Fiscal 2023 (3) Therapeutic Solutions Division (TSD)

1Q of Fiscal 2023 (4) Scientific Solutions Division (SSD)

Statement of Financial Position

Consolidated Cash Flows

• 02. Forecasts for Fiscal 2023

Fiscal2023Consolidated Forecasts

Fiscal2023Forecastsby Business Segment

• 03. TSD Growth Story

TSD aims to grow by focusing on targeted diseases

GI Endotherapyleverages its strong market position to derive high profits while improving the standard of care

Urology delivering strong growth at high profitability through innovative solutions that improve workflow and clinical outcomes

Respiratory EBUS scopes and needles are highly profitable, market leading solutions for lung cancer staging and diagnosis

@

Appendix

@

@

@

@

@

@

@

Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4

• Q&A5

• Q&A6

• Q&A7